ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)
CAPS Rating:
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
Recs
Twitter trolling pointed this one out...presented at JPM, decent pipeline, solid potential on a couple. Others are sketchy but the ISIS-smn seemed most interesting potential. Just seemed like a must own for the Fund.